Table 3.
Time (days) to BTA initiation in selected patient groups
| Characteristic | Medicare
|
Commercial
|
||||
|---|---|---|---|---|---|---|
| Number of patients | Mean (SD) | Median | Number of patients | Mean (SD) | Median | |
| All patients | 2,286 | 66.9 (101.3) | 27.0 | 5,774 | 66.1 (94.7) | 29.0 |
| Sex | ||||||
| Female | 973 | 58.3 (93.5) | 25.0 | 3,097 | 60.9 (89.8) | 27.0 |
| Male | 1,312 | 73.4 (106.4) | 29.0 | 2,676 | 72.0 (99.4) | 32.0 |
| Tumor type | ||||||
| Prostate | 812 | 83.7 (115.1) | 35.0 | 1,223 | 85.9 (113.8) | 37.0 |
| Breast | 599 | 62.8 (103.3) | 23.0 | 2,086 | 62.4 (91.7) | 27.0 |
| Lung | 686 | 53.7 (83.2) | 25.0 | 1,761 | 56.0 (80.0) | 28.0 |
| Other solid tumors | 189 | 56.0 (80.8) | 22.0 | 704 | 67.9 (96.0) | 29.0 |
| Agent used | ||||||
| Zoledronic acid | 1,202 | 47.9 (76.9) | 21.0 | 3,401 | 52.1 (81.0) | 24.0 |
| Pamidronate | 105 | 52.9 (72.2) | 24.0 | 216 | 53.8 (81.0) | 24.0 |
| Denosumab | 979 | 91.8 (122.8) | 37.0 | 2,157 | 89.5 (110.3) | 44.0 |
| With renal impairment diagnosisa | 408 | 69.4 (100.7) | 29.0 | 379 | 65.9 (91.5) | 32.0 |
Note:
a
In 12 months prior to bone metastasis diagnosis.
Abbreviations: BTA, bone-targeting agent; SD, standard deviation.